Non-covalent vs covalent BTK inhibitors in CLL

Jennifer Woyach, MD, Ohio State University College of Medicine, Columbus, OH, discusses the use of covalent and non-covalent Bruton’s tyrosine kinase (BTK) inhibitors in chronic lymphocytic leukemia (CLL) in the first and second-line settings, commenting on their efficacy and toxicity profile. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.